---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-004587"
form_type: "8-K"
ticker: "SLSN"
cik: "0000883107"
company_name: "SOLESENCE, INC."
filed_at: "2023-07-21T23:59:59+00:00"
generated_at: "2026-06-13T05:17:02.087506+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Mark E. Miller appointed to Nanophase Board of Directors

## Summary
- Appointed as independent director effective July 19, 2023.
- Will serve on Nominating & Governance, Audit & Finance, and Compensation committees.
- Miller brings 36 years of specialty materials and chemicals experience; former President & COO of Nagase Specialty Materials NA LLC.
- CEO Jess Jankowski stated Miller will strengthen governance and strategic guidance for skin health markets expansion.

## SEC filing metadata
- accession: 0001171843-23-004587
- form_type: 8-K
- ticker: SLSN
- cik: 0000883107
- company_name: SOLESENCE, INC.
- filed_at: 2023-07-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/883107/000117184323004587/0001171843-23-004587-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/883107/000117184323004587/f8k_072023.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-004587
- JSON: https://secwatch.observer/filing/0001171843-23-004587.json
- Plain text: https://secwatch.observer/filing/0001171843-23-004587.txt

## Key facts
- Executive change
  Mark E. Miller was appointed as Director at SOLESENCE, INC..
  - Action: appointed
  - Role: Director
  source text: On July 19, 2023, Mr. Mark E. Miller was appointed as a member of the Board of Directors (the “Board”) of Nanophase Technologies Corporation (the “Company”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/883107/000117184323004587/0001171843-23-004587-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.